Literature DB >> 28243791

Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems.

Christof Bernemann1, Julie Steinestel2, Martin Boegemann2, Andres J Schrader2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28243791     DOI： 10.1007/s00345-017-2024-6

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  21 in total

1.  Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR.

Authors:  Simone Fleige; Vanessa Walf; Silvia Huch; Christian Prgomet; Julia Sehm; Michael W Pfaffl
Journal:  Biotechnol Lett       Date:  2006-08-10       Impact factor: 2.461

2.  Blood Based Detection of Androgen Receptor Splice Variants in Patients with Advanced Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Jun Luo
Journal:  J Urol       Date:  2016-09-09       Impact factor: 7.450

Review 3.  Functional Studies on Viable Circulating Tumor Cells.

Authors:  Klaus Pantel; Catherine Alix-Panabières
Journal:  Clin Chem       Date:  2015-12-04       Impact factor: 8.327

4.  Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Authors:  Wendy Onstenk; Anieta M Sieuwerts; Jaco Kraan; Mai Van; Annemieke J M Nieuweboer; Ron H J Mathijssen; Paul Hamberg; Hielke J Meulenbeld; Bram De Laere; Luc Y Dirix; Robert J van Soest; Martijn P Lolkema; John W M Martens; Wytske M van Weerden; Guido W Jenster; John A Foekens; Ronald de Wit; Stefan Sleijfer
Journal:  Eur Urol       Date:  2015-07-15       Impact factor: 20.096

5.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

6.  The detection of EpCAM(+) and EpCAM(-) circulating tumor cells.

Authors:  Sanne de Wit; Guus van Dalum; Aufried T M Lenferink; Arjan G J Tibbe; T Jeroen N Hiltermann; Harry J M Groen; Cees J M van Rijn; Leon W M M Terstappen
Journal:  Sci Rep       Date:  2015-07-17       Impact factor: 4.379

7.  Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer.

Authors:  Takumi Takeuchi; Yumiko Okuno; Mami Hattori-Kato; Masayoshi Zaitsu; Koji Mikami
Journal:  Res Rep Urol       Date:  2016-01-28

8.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

Authors:  Howard I Scher; David Lu; Nicole A Schreiber; Jessica Louw; Ryon P Graf; Hebert A Vargas; Ann Johnson; Adam Jendrisak; Richard Bambury; Daniel Danila; Brigit McLaughlin; Justin Wahl; Stephanie B Greene; Glenn Heller; Dena Marrinucci; Martin Fleisher; Ryan Dittamore
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

9.  The Quantified Level of Circulating Prostate Stem Cell Antigen mRNA relative to GAPDH Level Is a Clinically Significant Indictor for Predicting Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy.

Authors:  Sung Han Kim; Weon Seo Park; Sang Jin Lee; Moon Kyung Choi; Seung Min Yeon; Jeong Nam Joo; Ara Ko; Eun Sik Lee; Jae Young Joung; Ho Kyung Seo; Jinsoo Chung; Kang Hyun Lee
Journal:  Biomed Res Int       Date:  2015-10-07       Impact factor: 3.411

10.  Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies.

Authors:  Yafeng Ma; Alison Luk; Francis P Young; David Lynch; Wei Chua; Bavanthi Balakrishnar; Paul de Souza; Therese M Becker
Journal:  Int J Mol Sci       Date:  2016-08-04       Impact factor: 5.923
View more
  2 in total

1.  Multiparametric liquid biopsy analysis in metastatic prostate cancer.

Authors:  Emmanuelle Hodara; Gareth Morrison; Alexander Cunha; Daniel Zainfeld; Tong Xu; Yucheng Xu; Paul W Dempsey; Paul C Pagano; Farideh Bischoff; Aditi Khurana; Samuel Koo; Marc Ting; Philip D Cotter; Mathew W Moore; Shelly Gunn; Joshua Usher; Shahrooz Rabizadeh; Peter Danenberg; Kathleen Danenberg; John Carpten; Tanya Dorff; David Quinn; Amir Goldkorn
Journal:  JCI Insight       Date:  2019-03-07

Review 2.  Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Authors:  Jun Luo; Gerhardt Attard; Steven P Balk; Charlotte Bevan; Kerry Burnstein; Laura Cato; Artem Cherkasov; Johann S De Bono; Yan Dong; Allen C Gao; Martin Gleave; Hannelore Heemers; Mayuko Kanayama; Ralf Kittler; Joshua M Lang; Richard J Lee; Christopher J Logothetis; Robert Matusik; Stephen Plymate; Charles L Sawyers; Luke A Selth; Howard Soule; Wayne Tilley; Nancy L Weigel; Amina Zoubeidi; Scott M Dehm; Ganesh V Raj
Journal:  Eur Urol       Date:  2017-12-16       Impact factor: 20.096
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.